Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 605-611

  Watanabe, Norio ^a,b   Yamamura, Keiko ^c   Suzuki, Yusuke ^d   Umegaki, Hiroyuki ^d   Shigeno, Katsuro ^c   Matsushita, Ryo ^a   Sai, Yoshimichi ^a   Miyamoto, Ken Ichi ^a   Yamada, Kiyofumi ^d  

^a KANAZAWA UNIVERSITY   (Japan)

^b Hashima City Hospital   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Consultation; Donepezil; Patient knowledge; Pharmacists

Indexed keywords

DONEPEZIL;

ABDOMINAL PAIN; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CAREGIVER; CLINICAL DEMENTIA RATING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONSULTATION; CONTROLLED STUDY; DIARRHEA; DONEPEZIL OUTPATIENT CONSULTATION SERVICE; DRUG WITHDRAWAL; EXCITEMENT; FEMALE; FOLLOW UP; FRUSTRATION; HEADACHE; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION PERSISTENCE; OUTPATIENT; PATIENT ATTITUDE; PHARMACIST; SCORING SYSTEM; SEX; SIDE EFFECT; TREMOR; VOMITING;

EID: 84885965668     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S34984     Document Type: Article

References (15)

1. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord. 2000;11(6): 299-313.
2. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000; 10(3):195-203.
3. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57(3):481-488.
4. Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin. 2004;20(8):1221-1225.
5. Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Int Psychogeriatr. 2008;20(4):800-806.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4th ed. Washington: American Psychiatric Association; 1994.
7. Kuzuya M, Enoki H, Izawa S, et al. Prevalence of oral intake difficulty and associated factors in disabled elderly. The Journal of Japanese Society for Parenteral and Enteral Nutrition. 2011;26:1265-1270.
8. Kuzuya M, Endo H, Umegaki H, et al. Factors influencing noncompliance with medication regimens in the elderly. Nihon Ronen Igakkai Zasshi. 2000;37(5):363-370.
9. Homma A, Imai Y, Hariguchi S, et al. Late Phase II Clinical Study of Acetylcholinesterase Inhibitor E2020 in Patients with Alzheimer-type Dementia. 12-weeks Double-blind, Placebo-Controlled Study, 3 mg/day, 5 mg/day. Clinical Evaluation. 1998;26:251-284.
10. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45-63.
11. Kröger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in The Netherlands: A retrospective cohort study. Drugs Aging. 2010;27(8):663-675.
12. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670-679.
13. Frankfort SV, Appels BA, de Boer A, et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry. 2005;20(12): 1167-1171.
14. Abughosh SM, Kogut SJ. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer Adherence. 2008;2:79-85.
15. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26(5): 403-407.